Marie-Claude Gingras, PhD
Program Manager
About Us
|
|
---|
Research
|
|
---|
Services
|
|
---|
The Cancer Research Program (CRP) benefits from new state-of-the-art facilities to conduct basic research at the Centre for Translational Biology (CTB), clinical cancer research at the Centre for Innovative Medicine (CIM), and evaluative cancer research at the Centre for Outcomes Research and Evaluation (CORE). Activities are supported by several newly enhanced technology platforms at the Glen site, including the Immunophenotyping, Histopathology, Biobank, Proteomics, Microscopy, Molecular Imaging, Small Animal Imaging Labs and Drug Discovery platforms.
The integration of basic, clinical and evaluative science has resulted in a new program that is able to pursue precision care research in collaboration with the Cedars Cancer Centre of the MUHC at the Glen. The CRP focuses on the mechanisms of etiology (hereditary predisposition), spread (metastasis) and progression of disease, with current studies in such domains as the identification of new markers and therapeutic targets, gene therapy, tumour suppressor genes, angiogenesis and radiosensitivity.
Review our research highlights and publications in the 2023 RI-MUHC Annual Report.
We are proud to celebrate the scientific achievements of our researchers and trainees in publications, grant competitions, honors and awards, and appointments, as well as in the mainstream press.
The Cancer Research Program (CRP) organizes and supports numerous speakers, seminars, and symposia throughout the year.
Researchers in the Cancer Research Program are involved in a multitude of research initiatives, including:
The Women's Health Research Unit (WHRU) conducts research in women's health and gynecology, specializing in gynecological oncology. Its DOvEE research clinic ensures that eligible women are offered easy, fast access to specialized medical examinations for the early detection and diagnosis of ovarian and endometrial cancers.
The Terry Fox Research Institute brings together RI-MUHC and other Canadian researchers in multiple joint projects, including the Canadian Ovarian Experimental Unified Resource (COEUR) for biomarker research in ovarian cancer, the Enhanced pancreatic cancer profiling for individualized care (EPPIC) and a project to study metastatic sarcomas.
The McGill University Thoracic and Upper GI Cancer Research Laboratories investigate the cellular, molecular, and genetic determinants of cancer metastasis from lung, esophageal and gastric malignancies.
Opal is an innovative mobile phone application that strives to make oncology patients' lives better. The app is also being tested at the Montreal Children’s Hospital.
The Quebec SmartCare Consortium, led by the Opal Health Informatics Group, brings together public and private healthcare organizations with the goal of demonstrating the efficiency of a solution to digitize all healthcare interactions and make all personal healthcare data accessible to patients by 2030.
The Cellular Therapy Laboratory (CTL) at the RI-MUHC enhances research capabilities using stem cells. The CTL collects and stores cells and tissues, provides screening services, undertakes fundamental research, adapts findings for clinical use, and participates in clinical trials.
The Centre for Applied Nanomedicine (CAN) at the RI-MUHC is a specialized technology platform and research hub for studies on extracellular vesicles (EVs) and nanosized extracellular particles (EPs).
The Rossy Cancer Network is a partnership of McGill's Faculty of Medicine, St. Mary’s Hospital, Jewish General Hospital and the McGill University Health Centre with a mission to improve cancer care quality.
The Henry C. Witelson Ocular Pathology Laboratory brings together clinicians and researchers to discover the mechanisms underlying various ocular diseases including uveal melanoma, retinoblastoma and other clinical ocular pathologies.
The Clinical Research Organization in Cancer (Q-CROC) coordinates a network of 16 of the most active health care institutions in oncology clinical research, accounting for more than 98% of recruiting studies in the province. The network has more than 250 investigators and 500 research professionals.
Contact the Cancer Research Program (CRP) at the RI-MUHC. We are happy to hear from you!
The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. The Institute, which is affiliated with the Faculty of Medicine of McGill University, is the research arm of the McGill University Health Centre (MUHC) – an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 460 researchers and close to 1,200 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC.